Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer

Documenti analoghi

• Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
  di: Suda, Kenichi, et al.
  Pubblicazione: (2021)
• Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
  di: Occhipinti, Mario, et al.
  Pubblicazione: (2021)
• Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
  di: Soomin Kim, et al.
  Pubblicazione: (2025-02-01)
• Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
  di: Li, Xin, et al.
  Pubblicazione: (2018)
• Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
  di: Krawczyk, Paweł, et al.
  Pubblicazione: (2012)